Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22712
Title: Abnormalities at three musculoskeletal sites on whole-body positron emission tomography/computed tomography can diagnose polymyalgia rheumatica with high sensitivity and specificity.
Austin Authors: Owen, Claire E ;Poon, Aurora M T ;Yang, Victor;McMaster, Christopher ;Lee, Sze Ting ;Liew, David F L ;Leung, Jessica L Y ;Scott, Andrew M ;Buchanan, Russell R C 
Affiliation: Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
School of Cancer Medicine, La Trobe University, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Department of Rheumatology, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
Issue Date: Sep-2020
metadata.dc.date: 2020-02-23
Publication information: European Journal of Nuclear Medicine and Molecular Imaging 2020; 47(10): 2461-2468
Abstract: To evaluate the sensitivity and specificity of PET/CT findings in PMR and generate a diagnostic algorithm utilizing a minimum number of musculoskeletal sites. Steroid-naïve patients with newly diagnosed PMR (2012 EULAR/ACR classification criteria) were prospectively recruited to undergo whole-body 18F-FDG PET/CT. Each PMR case was age- and sex-matched to four PET/CT controls. Control scan indication, diagnosis and medical history were extracted from the clinical record. Qualitative and semi-quantitative scoring (maximum standardized uptake value [SUVmax]) of abnormal 18F-FDG uptake at 21 musculoskeletal sites was undertaken for cases and controls. Results informed the development of a novel PET/CT diagnostic algorithm using a classification and regression trees (CART) method. Thirty-three cases met the inclusion criteria and were matched to 132 controls. Mean age was 68.6 ± 7.4 years for cases compared with 68.2 ± 7.3 for controls, and 54.5% were male. Median CRP was 49 mg/L (32-65) and ESR 41.5 mm/h (24.6-64.4) in the PMR group. The predominant control indication for PET/CT was malignancy (63.6%). Individual musculoskeletal sites proved insufficient for diagnostic purposes. A novel algorithm comprising 18F-FDG uptake ≥ 2 adjacent to the ischial tuberosities in combination with either abnormalities at the peri-articular shoulder or interspinous bursa achieved a sensitivity of 90.9% and specificity of 92.4% for diagnosing PMR. The presence of abnormal 18F-FDG uptake adjacent to the ischial tuberosities together with findings at the peri-articular shoulder or interspinous bursa on whole-body PET/CT is highly sensitive and specific for a diagnosis of PMR. Clinical Trial Registration: Australian New Zealand Clinical Trials Registry, http://www.anzctr.org.au, ACTRN1261400696695.
URI: http://ahro.austin.org.au/austinjspui/handle/1/22712
DOI: 10.1007/s00259-020-04731-z
ORCID: 0000-0002-2694-5411
0000-0003-2432-5451
0000-0001-8641-456X
0000-0001-8451-8883
0000-0002-6656-295X
PubMed URL: 32090280
Type: Journal Article
Subjects: Diagnosis
Polymyalgia rheumatica
Sensitivity
Specificity
Whole-body positron emission tomography/computed tomography
Appears in Collections:Journal articles

Show full item record

Page view(s)

20
checked on Nov 28, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.